Diabetes Mellitus, Type 1

Metabolic Diseases
80
Pipeline Programs
19
Companies
50
Clinical Trials
6 recruiting
23
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
20
1
12
1
19
27
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
3100%
+ 84 programs with unclassified modality

On Market (23)

Approved therapies currently available

Sanofi
APIDRAApproved
insulin glulisine
Sanofi
Insulin Analog [EPC]intravenous, subcutaneous2004
Sanofi
APIDRA SOLOSTARApproved
insulin glulisine
Sanofi
Insulin Analog [EPC]subcutaneous2004
Eli Lilly and Company
BASAGLARApproved
insulin glargine
Eli Lilly and Company
Insulin Analog [EPC]subcutaneous2015
U
EMPAGLIFLOZINApproved
empagliflozin
Unknown Company
oral
Eli Lilly and Company
HUMALOGApproved
insulin lispro
Eli Lilly and Company
Insulin Analog [EPC]injection1996
Eli Lilly and Company
HUMALOG KWIKPENApproved
insulin lispro
Eli Lilly and Company
Insulin Analog [EPC]subcutaneous2015
Eli Lilly and Company
HUMALOG MIX 50/50Approved
insulin lispro
Eli Lilly and Company
Insulin Analog [EPC]injection1999
Eli Lilly and Company
HUMALOG MIX 50/50 KWIKPENApproved
insulin lispro
Eli Lilly and Company
Insulin Analog [EPC]injection1999
Eli Lilly and Company
HUMALOG MIX 50/50 PENApproved
insulin lispro
Eli Lilly and Company
Insulin Analog [EPC]injection1999
Eli Lilly and Company
HUMALOG MIX 75/25Approved
insulin lispro
Eli Lilly and Company
Insulin Analog [EPC]injection1999
Eli Lilly and Company
HUMALOG MIX 75/25 KWIKPENApproved
insulin lispro
Eli Lilly and Company
Insulin Analog [EPC]injection1999
Eli Lilly and Company
HUMALOG MIX 75/25 PENApproved
insulin lispro
Eli Lilly and Company
Insulin Analog [EPC]injection1999
Eli Lilly and Company
HUMALOG PENApproved
insulin lispro
Eli Lilly and Company
Insulin Analog [EPC]injection1996
Eli Lilly and Company
HUMALOG TEMPO PENApproved
insulin lispro
Eli Lilly and Company
Insulin Analog [EPC]injection1996
Boehringer Ingelheim
JARDIANCEApproved
empagliflozin
Boehringer Ingelheim
Sodium-Glucose Cotransporter 2 Inhibitor [EPC]oral2014
Novo Nordisk
LEVEMIRApproved
insulin detemir
Novo Nordisk
injection2005
Novo Nordisk
LEVEMIR FLEXPENApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
Novo Nordisk
LEVEMIR FLEXTOUCHApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
Novo Nordisk
LEVEMIR INNOLETApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
Novo Nordisk
LEVEMIR PENFILLApproved
insulin detemir
Novo Nordisk
Insulin Analog [EPC]subcutaneous2005
Eli Lilly and Company
LYUMJEVApproved
insulin lispro-aabc
Eli Lilly and Company
Insulin Analog [EPC]injection2020
AstraZeneca
SYMLINApproved
pramlintide acetate
AstraZeneca
subcutaneous2005
Novo Nordisk
TRESIBAApproved
insulin degludec
Novo Nordisk
Insulin Analog [EPC]subcutaneous2015

Competitive Landscape

19 companies ranked by most advanced pipeline stage

Novo Nordisk
Novo NordiskBAGSVAERD DENMARK, Denmark
32 programs
13
1
5
2
Insulin DegludecPhase 41 trial
Insulin glarginePhase 41 trial
Faster aspartPhase 31 trial
Insulin Aspart, BIAsp 70, BIAsp50, Human InsulinPhase 31 trial
Insulin detemirPhase 31 trial
+27 more programs
Active Trials
NCT05483803Completed100Est. Dec 2023
NCT07052292Active Not Recruiting125Est. Jan 2026
NCT03579615Completed18Est. Aug 2022
+28 more trials
Eli Lilly and Company
Eli Lilly and CompanyINDIANAPOLIS, IN
11 programs
4
3
1
LYUMJEV(Insulin Lispro)Phase 42 trials
BASAGLAR(Glargine)Phase 31 trial
GlarginePhase 31 trial
Human Insulin Inhalation PowderPhase 31 trial
LY2605541Phase 11 trial
+6 more programs
Active Trials
NCT04612257Terminated10Est. Jun 2022
NCT03758430Completed28Est. Aug 2020
NCT01784211Completed76Est. Nov 2013
+8 more trials
Boehringer Ingelheim
Boehringer IngelheimINGELHEIM, Germany
7 programs
4
3
1
EmpagliflozinPhase 3Small Molecule1 trial
EmpagliflozinPhase 3Small Molecule1 trial
LY2963016Phase 31 trial
BI 10773Phase 21 trial
EmpagliflozinPhase 2Small Molecule1 trial
+2 more programs
Active Trials
NCT01392560Completed52Est. Aug 2012
NCT02632747Completed31Est. Jul 2019
NCT01969747Completed75Est. Apr 2014
+4 more trials
Sanofi
SanofiPARIS, France
3 programs
1
1
INSULIN GLULISINEPhase 41 trial
Insuline GlulisinePhase 31 trial
French National Cohort of People With Type 1 DiabetesN/A
Active Trials
NCT00546702Completed142Est. Feb 2005
NCT00964574Completed68Est. Jul 2010
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
1
1
Pramlintide acetatePhase 31 trial
Active Trials
NCT00042458Completed296Est. Mar 2003
Pfizer
PfizerNEW YORK, NY
5 programs
1
1
3
Inhaled human insulinPhase 31 trial
Inhaled human insulinPhase 31 trial
Subcutaneous InsulinPhase 31 trial
Inhaled insulinPhase 21 trial
Pancreatic Islets of Langerhans Cell TransplantPhase 11 trial
Active Trials
NCT00605592Unknown20Est. Jan 2012
NCT00143104Completed20Est. Oct 2006
NCT00424333Completed320Est. Oct 2000
+2 more trials
Alkermes
AlkermesDUBLIN 4, Ireland
4 programs
1
1
2
Human Insulin Inhalation PowderPhase 3
Human Insulin Inhalation PowderPhase 3
Insulin glarginePhase 2/3
insulinPhase 2
VP
1 program
1
VX-880Phase 31 trial
Active Trials
NCT04786262Recruiting52Est. Jun 2030
Diamyd Medical
Diamyd MedicalSweden - Stockholm
6 programs
1
1
4
DiamydPhase 21 trial
DiamydPhase 21 trial
GAD-AlumPhase 21 trial
GAD-AlumPhase 21 trial
GAD-alumPhase 1/21 trial
+1 more programs
Active Trials
NCT02352974Completed12Est. Oct 2019
NCT05351879Completed6Est. Aug 2023
NCT05683990Recruiting16Est. Mar 2028
+3 more trials
Beta Bionics
Beta BionicsIRVINE, CA
2 programs
1
Insulin LisproPhase 21 trial
Bionic PancreasN/A1 trial
Active Trials
NCT05168657Completed54Est. May 2023
NCT02971228Completed13Est. Jun 2017
T-Therapeutics
T-TherapeuticsUK - Cambridge
2 programs
1
OPT101Phase 11 trial
Ear-EEG systemN/A
Active Trials
NCT05428943CompletedEst. Feb 2024
Roche
RocheSTAVANGER NORWAY, Norway
3 programs
Accu-Chek® Solo micropump systemN/A1 trial
Artificial PancreasN/A1 trial
Aviva Expert blood glucose meterN/A1 trial
Active Trials
NCT03478969Completed181Est. May 2020
NCT02844517Completed43Est. Oct 2017
NCT01460446Completed218Est. Sep 2012
Insulet
InsuletACTON, MA
3 programs
French National Cohort of People With Type 1 DiabetesN/A
OmnipodN/A1 trial
Omnipod 5 SystemN/A1 trial
Active Trials
NCT04226378CompletedEst. Feb 2020
NCT05923827Active Not RecruitingEst. Aug 2025
UNEEG Medical
UNEEG MedicalDenmark - Allerod
2 programs
Ear-EEG systemN/A1 trial
hyposafe H02N/A1 trial
Active Trials
NCT03022058Completed12Est. Nov 2017
NCT02925676Terminated8Est. Sep 2018
DS
Daiichi SankyoChina - Shanghai
1 program
Colesevelam HClN/A1 trial
Active Trials
NCT00938405Completed45Est. Dec 2009
DiaMonTech
DiaMonTechGermany - Berlin
1 program
Feasibility Study of Blood Glucose Monitoring With the Non-invasive Medical Device D-BaseN/A1 trial
Active Trials
NCT05169034Terminated25Est. Aug 2022
Abbott
AbbottABBOTT PARK, IL
1 program
French National Cohort of People With Type 1 DiabetesN/A1 trial
Active Trials
NCT04657783Recruiting15,000Est. Jun 2035
Alder Therapeutics
Alder TherapeuticsSweden - Solna
1 program
Online self-compassion interventionN/A1 trial
Active Trials
NCT03504605Completed344Est. Jul 2019
Diabeloop
DiabeloopFrance - Grenoble
1 program
Use of the DBLG1 systemN/A1 trial
Active Trials
NCT05628532CompletedEst. Apr 2024

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
Novo NordiskInsulin Degludec
Novo NordiskInsulin glargine
Eli Lilly and CompanyInsulin Lispro
SanofiINSULIN GLULISINE
Novo NordiskInsulin icodec
Novo Nordiskinsulin icodec
Vertex PharmaceuticalsVX-880
Novo NordiskFaster aspart
Boehringer IngelheimEmpagliflozin
Boehringer IngelheimEmpagliflozin
Eli Lilly and CompanyGlargine
Eli Lilly and CompanyGlargine
Boehringer IngelheimLY2963016
Novo NordiskInsulin Aspart, BIAsp 70, BIAsp50, Human Insulin
Eli Lilly and CompanyHuman Insulin Inhalation Powder

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 10,228 patients across 50 trials

NCT03668808Novo NordiskInsulin Degludec

Comparison of Insulin Degludec With Insulin Glargine U100 for Adults With Type 1 Diabetes Crossing Multiple Time Zones.

Start: Nov 2018Est. completion: Sep 202025 patients
Phase 4Completed
NCT01440439Novo NordiskInsulin glargine

Comparing Long-acting Insulins During Exercise in Type 1 Diabetes

Start: Nov 2011Est. completion: Jun 201230 patients
Phase 4Unknown

A Study on the Effect of 2 Pen Devices on HbA1c

Start: Oct 2009Est. completion: Jul 2011263 patients
Phase 4Completed
NCT00964574SanofiINSULIN GLULISINE

Test of the Efficacy and Safety of Insulin Glulisine Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus

Start: Jul 2009Est. completion: Jul 201068 patients
Phase 4Completed

A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes

Start: Aug 2025Est. completion: Dec 2026877 patients
Phase 3Recruiting

A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)

Start: Apr 2021Est. completion: Dec 2022582 patients
Phase 3Completed

A Safety, Tolerability, and Efficacy Study of VX-880 in Participants With Type 1 Diabetes

Start: Mar 2021Est. completion: Jun 203052 patients
Phase 3Recruiting

Research Study to Compare a New Medicine "Fast-acting Insulin Aspart" to Another Medicine "Insulin Aspart" in Chinese People With Diabetes

Start: Oct 2020Est. completion: Aug 2022331 patients
Phase 3Completed

Empagliflozin as Adjunctive to Insulin Therapy Over 26 Weeks in Patients With T1DM (EASE-3)

Start: Dec 2015Est. completion: Sep 2017977 patients
Phase 3Completed

Empagliflozin as Adjunctive to InSulin thErapy Over 52 Weeks in Patients With Type 1 Diabetes Mellitus (EASE-2)

Start: Jun 2015Est. completion: Oct 2017730 patients
Phase 3Completed

A Study in Participants With Type 1 Diabetes Mellitus

Start: Jan 2012Est. completion: Jun 2014455 patients
Phase 3Completed

A Study in Participants With Type I Diabetes Mellitus

Start: Jan 2012Est. completion: Feb 20141,114 patients
Phase 3Completed

A Study in Adults With Type 1 Diabetes

Start: Aug 2011Est. completion: Apr 2013536 patients
Phase 3Completed
NCT00888732Novo NordiskInsulin Aspart, BIAsp 70, BIAsp50, Human Insulin

A Comparison of Pharmacodynamics and Pharmacokinetics of Insulin Aspart, BIAsp70, BIAsp50 and Fast-acting Human Insulin

Start: Jun 2009Est. completion: Jun 201024 patients
Phase 3Completed
NCT00356109Eli Lilly and CompanyHuman Insulin Inhalation Powder

Evaluate the Efficacy of Insulin Patients With Type 1 Diabetes

Start: Aug 2006Est. completion: May 2008494 patients
Phase 3Completed
NCT00546702SanofiInsuline Glulisine

Glulisine + Lantus in Type I Patients

Start: Sep 2004Est. completion: Feb 2005142 patients
Phase 3Completed
NCT00137046PfizerSubcutaneous Insulin

Efficacy and Safety of Inhaled Insulin Compared With Subcutaneous Human Insulin Therapy in Adults With Type 1 Diabetes

Start: May 2002Est. completion: Dec 2008582 patients
Phase 3Terminated
NCT00042458AstraZenecaPramlintide acetate

Evaluation of Dose-titration of Pramlintide During Initiation of Therapy in Patients Trying to Improve Glucose Control

Start: Apr 2002Est. completion: Mar 2003296 patients
Phase 3Completed

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

Start: Feb 2001Est. completion: Nov 2001752 patients
Phase 3Completed
NCT00424437PfizerInhaled human insulin

Six Month Clinical Trial Assessing Efficacy And Safety Of Inhaled Insulin In Type 1 Diabetes Mellitus.

Start: Sep 1999Est. completion: Sep 2000320 patients
Phase 3Completed
NCT00424333PfizerInhaled human insulin

Six Month Clinical Trial Assessing Efficacy and Safety of Inhaled Insulin in Type 1 Diabetes

Start: May 1999Est. completion: Oct 2000320 patients
Phase 3Completed

Study to Evaluate the Safety and Feasibility of Diamyd® in Individuals at Risk for Type 1 Diabetes

Start: Jul 2024Est. completion: Mar 202816 patients
Phase 2Recruiting
NCT03816761Novo NordiskFast-acting insulin aspart

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

Start: Feb 2019Est. completion: Jun 201924 patients
Phase 2Completed

Diamyd Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes

Start: Dec 2017Est. completion: Apr 2021109 patients
Phase 2Completed

Feasibility Trial Testing the Bionic Pancreas With ZP4207

Start: Nov 2016Est. completion: Jun 201713 patients
Phase 2Completed

Empagliflozin and ACEi- Effects on Hyperfiltration: BETWEEN Study

Start: May 2016Est. completion: Jul 201931 patients
Phase 2Completed
NCT02702011Boehringer Ingelheimempagliflozin medium dose

Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus

Start: Mar 2016Est. completion: Oct 201648 patients
Phase 2Completed

EDCR Study - Etanercept Diamyd Combination Regimen -Open Trial to Evaluate Safety in Children With Type 1 Diabetes

Start: May 2015Est. completion: Feb 201920 patients
Phase 2Completed
NCT01969747Boehringer IngelheimEmpagliflozin medium placebo

Empagliflozin add-on to Insulin in Type 1 Diabetes Mellitus Over 28 Days

Start: Nov 2013Est. completion: Apr 201475 patients
Phase 2Completed

DIABGAD - Trial to Preserve Insulin Secretion in Type 1 Diabetes Using GAD-Alum (Diamyd) in Combination With Vitamin D and Ibuprofen

Start: Feb 2013Est. completion: Mar 201760 patients
Phase 2Completed

Safety and Efficacy of Empagliflozin (BI 10773) in Type 1 Diabetes Mellitus Patients With or Without Renal Hyperfiltration

Start: Jun 2011Est. completion: Aug 201252 patients
Phase 2Completed
NCT00143104PfizerInhaled insulin

To Examine the Lung When People With Diabetes Take an Inhaled Form of Insulin, Compared to Subcutaneous Insulin.

Start: Dec 2004Est. completion: Oct 200620 patients
Phase 2Completed

Evaluation of a Booster Administration of GAD-alum (Diamyd®) in Individuals With Type 1 Diabetes

Start: May 2022Est. completion: Aug 20236 patients
Phase 1/2Completed

A Research Study of a New Medicine NNC0363-1063 in Participants With Type 1 Diabetes

Start: Dec 2025Est. completion: May 202636 patients
Phase 1Recruiting

A Study to See the Effect of NNC0194-0499 Alone or in Combination With Semaglutide on Blood Sugar Control in People Living With Type 1 Diabetes

Start: Jul 2025Est. completion: Sep 202696 patients
Phase 1Recruiting

A Study to Test How Insulin NNC0471-0119 H Works in the Body in Participants With Type 1 Diabetes When Given by an Insulin Pump

Start: Jan 2025Est. completion: Jul 202543 patients
Phase 1Completed

A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes

Start: Nov 2024Est. completion: May 2026154 patients
Phase 1Recruiting

Research Study in Japan to Compare Dasiglucagon With Glucagon in Treating Very Low Levels of Blood Sugar in Asian Adults With Type 1 Diabetes and Testing of Dasiglucagon for the Same Condition in Japanese Adolescents

Start: Sep 2024Est. completion: Jul 202538 patients
Phase 1Completed

OPT101 in Type 1 Diabetes Patients

Start: Sep 2022Est. completion: Feb 2024
Phase 1Completed

A Study to Look at How Insulin NNC0471-0119 Works in the Body in People With Type 1 Diabetes When Injected by Insulin Pump

Start: Mar 2022Est. completion: Sep 202219 patients
Phase 1Completed

A Multiple Dose Study Investigating Pharmacokinetics and Pharmacodynamics of Subcutaneous NNC0363-0845 in Participants With Type 1 Diabetes Pharmacokinetics and Pharmacodynamics: How Insulin NNC0363-0845 is Transported Throughout the Body and How It Works

Start: Dec 2021Est. completion: May 202230 patients
Phase 1Completed

A Research Study to Look at How Faster Aspart Works in Chinese People With Type 1 Diabetes or Type 2 Diabetes

Start: Apr 2021Est. completion: Jul 202223 patients
Phase 1Completed

A Study to Look at How Safe Insulin NNC0471-0119 is and How it Works in People With Type 1 Diabetes Mellitus

Start: Nov 2020Est. completion: Nov 202148 patients
Phase 1Completed

A Study to Look at How Safe NNC0268-0965 is in Healthy People and People With Type 1 Diabetes

Start: Jun 2019Est. completion: Dec 201978 patients
Phase 1Completed

A Research Study of How Different Amounts of a New Medicine NNC0148-0287 C (Insulin 287) Works on the Blood Sugar of People Who Are Japanese With Type 1 Diabetes When Given Once a Week

Start: Dec 2018Est. completion: Dec 201924 patients
Phase 1Completed

A Research Study of How Different Doses of a New Medicine NNC0148-0287 C (Insulin 287) Work on the Blood Sugar in People With Type 1 Diabetes When it is Taken Once a Week

Start: Nov 2018Est. completion: Jun 202066 patients
Phase 1Completed
NCT03723759Novo NordiskFaster Aspart 200 U/mL

A Research Study Looking at How Faster Aspart Injected in Double Concentration Works in the Body of People With Type 1 Diabetes Mellitus

Start: Oct 2018Est. completion: Mar 201956 patients
Phase 1Completed

A Study of LY900014 in Japanese Participants With Type 1 Diabetes Mellitus

Start: Feb 2018Est. completion: Jul 201831 patients
Phase 1Completed

A Study of LY900014 in Participants With Type 1 Diabetes on Insulin Injection Therapy

Start: Mar 2016Est. completion: Jul 201630 patients
Phase 1Completed

GAD-Alum (Diamyd) Administered Into Lymph Nodes in Combination With Vitamin D in Type 1 Diabetes (DIAGNODE-1)

Start: Jan 2015Est. completion: Oct 201912 patients
Phase 1Completed

Related Jobs in Metabolic Diseases

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

19 late-stage (Phase 3) programs — potential near-term approvals
6 actively recruiting trials targeting 10,228 patients
19 companies competing in this space